How many stocks are there of Formycon?
The current number of stocks of Formycon is 16.05 M undefined.
Formycon Stocks 2024
Formycon Stocks
16.05 M
Ticker
FYB.DE
ISIN
DE000A1EWVY8
WKN
A1EWVY
In 2024, Formycon had 16.05 M outstanding stocks, a 0% change from the 16.05 M stocks in the previous year.
The Formycon Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2029e | 16.05 |
| 2028e | 16.05 |
| 2027e | 16.05 |
| 2026e | 16.05 |
| 2025e | 16.05 |
| 2024e | 16.05 |
| 2023 | 16.05 |
| 2022 | 13.88 |
| 2021 | 11 |
| 2020 | 11 |
| 2019 | 10 |
| 2018 | 9.42 |
| 2017 | 9.34 |
| 2016 | 9.1 |
| 2015 | 9.08 |
| 2014 | 8.63 |
| 2013 | 8.6 |
| 2012 | 7.41 |
| 2011 | 7.24 |
| 2010 | 7.24 |
Formycon shares outstanding DE000A1EWVY8 · A1EWVY
The number of shares was Formycon in 2023 — This indicates how many shares 16.049 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Formycon earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Formycon's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Formycon’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Formycon's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2010 | 7.24 M Aktien |
| 2011 | 7.24 M Aktien |
| 2012 | 7.41 M Aktien |
| 2013 | 8.6 M Aktien |
| 2014 | 8.63 M Aktien |
| 2015 | 9.08 M Aktien |
| 2016 | 9.1 M Aktien |
| 2017 | 9.34 M Aktien |
| 2018 | 9.42 M Aktien |
| 2019 | 10 M Aktien |
| 2020 | 11 M Aktien |
| 2021 | 11 M Aktien |
| 2022 | 13.88 M Aktien |
| 2023 | 16.05 M Aktien |
| 2024e | 16.05 M Aktien |
| 2025e | 16.05 M Aktien |
| 2026e | 16.05 M Aktien |
| 2027e | 16.05 M Aktien |
| 2028e | 16.05 M Aktien |
| 2029e | 16.05 M Aktien |
Formycon Aktienanalyse
What does Formycon do?
Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Formycon's Shares Outstanding
Formycon's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Formycon’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Formycon’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Formycon’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Formycon Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Formycon are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Formycon evolved in recent years?
The number of shares of Formycon has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Formycon as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Formycon?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Formycon pay?
Over the past 12 months, Formycon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Formycon is expected to pay a dividend of 0 EUR.
What is the dividend yield of Formycon?
The current dividend yield of Formycon is .
When does Formycon pay dividends?
Formycon pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Formycon?
Formycon paid dividends every year for the past 0 years.
What is the dividend of Formycon?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Formycon located?
Formycon is assigned to the 'Health' sector.
Wann musste ich die Aktien von Formycon kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Formycon from 6/30/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.
When did Formycon pay the last dividend?
The last dividend was paid out on 6/30/2024.
What was the dividend of Formycon in the year 2023?
In the year 2023, Formycon distributed 0 EUR as dividends.
In which currency does Formycon pay out the dividend?
The dividends of Formycon are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Formycon stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Formycon
Our stock analysis for Formycon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
